Lilly To Decide Next Steps After Formal FDA 'Nay' For First Chinese PD-1
A Chance To Reflect?
The official verdict is in for sintilimab and the results are not surprising. But some view the setback for "Made In China" innovation as a chance to reflect and move forward.
You may also be interested in...
The antibody-drug conjugate market is emerging as the next battleground for intense competition in China, with global partnerships becoming essential to win, as evidenced by a major new alliance between Innovent and Sanofi.
Merck’s Keytruda and BMS’s Opdivo could be tough competitors in esophageal cancer, but the Novartis/BeiGene partnership also has an anti-TIGIT drug up its sleeve.
Glenmark is set to initiate a Phase I study for its inhibitor of immuno-oncology target hematopoietic progenitor kinase 1 (HPK1), a segment that has seen increased activity over the recent past with BeiGene, Nimbus and Treadwell Therapeutics among those advancing their molecules.